| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | ATG8F ELISA Kit; Autophagy-related protein LC3 B ELISA Kit; Autophagy-related ubiquitin-like modifier LC3 B ELISA Kit; LC3B ELISA Kit; LC3II ELISA Kit; MAP1 light chain 3 like protein 2 ELISA Kit; MAP1 light chain 3-like protein 2 ELISA Kit; MAP1A/1BLC3 ELISA Kit; MAP1A/MAP1B LC3 B ELISA Kit; MAP1A/MAP1B light chain 3 B ELISA Kit; MAP1ALC3 ELISA Kit; MAP1LC3B a ELISA Kit; Map1lc3b ELISA Kit; Microtubule associated protein 1 light chain 3 beta ELISA Kit; Microtubule-associated protein 1 light chain 3 beta ELISA Kit; Microtubule-associated proteins 1A/1B light chain 3B ELISA Kit; MLP3B_HUMAN ELISA Kit |
| Assay Time | |
| Assay Type | |
| Detection Range | |
| Detection Wavelength | |
| Product Type | |
| Reactivity | |
| Sample Type(s) | serum, plasma, tissue homogenates, cell lysates |
| Sensitivity | |
| Species | |
| Target | |
| UniProt # |
Background
Microtubule-associated proteins 1A/1B light chain 3B(MAP1LC3B) is a biological molecule commonly studied in cancer research. Hormones and peptide mediators support systemic communication across organs and physiological states.
UniProt: Q9GZQ8
Biological context
Researchers often monitor Microtubule-associated proteins 1A/1B light chain 3B(MAP1LC3B) in serum, plasma, tissue homogenates, and cell lysates to better understand themes such as tumor microenvironment biology, cell proliferation and apoptosis, and metastasis and invasion pathways. In many model systems, measured levels can shift with physiology, experimental perturbation, or disease-associated changes, making careful biological interpretation important.
Interpreting changes in measured levels
Depending on sample matrix and study design, increases or decreases in Microtubule-associated proteins 1A/1B light chain 3B(MAP1LC3B) may reflect differences in expression, secretion, turnover, or compartmentalization rather than a single mechanism. Interpretation is typically strengthened by evaluating related molecules (for example, cell-cycle regulators, invasion/ECM markers, and immune-oncology mediators) and by keeping pre-analytical variables consistent across groups.
Nomenclature
In publications and databases, Microtubule-associated proteins 1A/1B light chain 3B(MAP1LC3B) may also appear under names such as ATG8F and Autophagy-related protein LC3 B. When comparing studies, confirm that the reported analyte refers to the same molecule and species context.
Why ELISA data are widely used
ELISA is a common approach for quantitative measurement of proteins and biomarkers in complex samples, enabling comparisons across experimental groups and time points. When integrating results with other readouts, consider species biology, sample type, and the broader pathway context that Microtubule-associated proteins 1A/1B light chain 3B(MAP1LC3B) participates in.
Can’t Find What You’re Looking For? We can help you source the best match or customize an ELISA solution for your study. Options may include alternative target synonyms, different species reactivity, sample type/matrix compatibility (serum/plasma/lysate/supernatant), assay format (sandwich/competitive), sensitivity/range, detection chemistry (colorimetric/fluorescent/chemiluminescent), plate format (pre-coated/uncoated, strips vs full plate), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
Synergistic anticancer effects of camptothecin and sotorasib in KRAS-mutated pancreatic ductal adenocarcinoma
PS Ramalingam, G Chellasamy, MS Hussain,Frontiers in Pharmacology,2025
Interplay of endothelial-mesenchymal transition inflammation and autophagy in proliferative diabetic retinopathy pathogenesis
K Himaja,Heliyon,2024
Autophagy Markers Are Altered in Alzheimer's Disease, Dementia with Lewy Bodies and Frontotemporal Dementia
A Hosney,International journal of molecular sciences,2024
CytotoxiC effeCt of ZiZiphus spina-Christi extraCt alone and in Combination with doxorubiCin on breast CanCer Cells
S Wu,/,2024